RCT | Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter (thread – click for more)

Hereditary angioedema is a rare disease associated with unpredictable, recurrent angioedema attacks that can be life-threatening.

New study data support the use of garadacimab as a potential prophylactic therapy in adolescents and adults: https://t.co/xlxoA3J3sh ? pic.twitter.com/VqCOHnaQAp

— The Lancet (@TheLancet) March 6, 2023